Antimicrobial susceptibility testing in biofilm-growing bacteria

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

Vaccines for the elderly

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

C. Pina-Vaz, F. Sansonetty, A. G. Rodrigues, S. Costa-Oliveira, C

Benchmarking inappropriate empirical antibiotic treatment

Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients R. Cantón, N. Cobos,

Gut bacterial microbiota and obesity

I.J. Schalk Clinical Microbiology and Infection

M.A.C. Broeren, Y. Maas, E. Retera, N.L.A. Arents

Approach to diagnosis of infective endocarditis

S. Wagenpfeil, A. Neiss, K. Banz, P. Wutzler

P. Clarke, S. Murchan, E.G. Smyth, H. Humphreys

Control of multidrug-resistant Gram-negative bacteria in low- and middle-income countries—high impact interventions without much resources N. Singh,

The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram- positive bacteria M.J. Rybak Clinical Microbiology and Infection

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

R. Cantón Clinical Microbiology and Infection

Nosocomial spread of Pseudomonas aeruginosa producing the metallo-β-lactamase VIM-2 in a Spanish hospital: clinical and epidemiological implications

P. Nordmann, L. Poirel Clinical Microbiology and Infection

A.E. Muller, U. Theuretzbacher, J.W. Mouton

Louis Pasteur, from crystals of life to vaccination

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

Should standardized susceptibility testing for microbial biofilms be introduced in clinical practice? T. Coenye, D. Goeres, F. Van Bambeke, T. Bjarnsholt

How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach D. Guillemot Clinical Microbiology.

S. Khelaifia, M. Drancourt Clinical Microbiology and Infection

Vector control: a cornerstone in the malaria elimination campaign

Switch to oral antibiotics in the treatment of infective endocarditis is not associated with increased risk of mortality in non–severely ill patients

Sofie Arens, Jan Verhaegen, Ludo Verbist

A. Oliver, A. Mena Clinical Microbiology and Infection

Multicenter study of the in vitro activity of cefepime in comparison with five other broad- spectrum antibiotics against clinical isolates of Gram-positive.

Training for the infectious diseases speciality in Norway

Isospora belli Clinical Microbiology and Infection

Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice J.E. Arends, P.A.M. Kracht, A.I.M. Hoepelman Clinical.

The exclusion of dead bacterial cells is essential for accurate molecular analysis of clinical samples G.B. Rogers, P. Marsh, A.F. Stressmann, C.E. Allen,

Rapidly growing mycobacteria in Singapore, 2006–2011

In vitro selection of antibiotic resistance in Pseudomonas aeruginosa

Levofloxacin in the treatment of ventilator-associated pneumonia

R. Bitterman, M. Paul, D. Polak, Y. Geffen

Isolation rate, T-serotyping and susceptibility to antibiotics of Group A Streptococcus from pediatric infections in Athens* M. Kanellopoulou, A. Makri,

Metagenomics and probiotics

J. Garau Clinical Microbiology and Infection

Systematic review of antibiotic consumption in acute care hospitals

Harmonised monitoring of antimicrobial resistance in Salmonella and Campylobacter isolates from food animals in the European Union S. Bronzwaer Clinical.

Abstracts cont. Clinical Microbiology and Infection

Benchmarking inappropriate empirical antibiotic treatment

P.M. Hawkey Clinical Microbiology and Infection

A novel fluorescence in situ hybridization test for rapid pathogen identification in positive blood cultures A. Makristathis, S. Riss, A.M. Hirschl

Reducing antibiotic use in influenza: challenges and rewards

Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida

A.P. Underwood, J. Green Clinical Microbiology and Infection

Antimicrobial drug development – the past, the present, and the future

Circulation of international clones of levofloxacin non-susceptible Streptococcus pneumoniae in Taiwan Y.-C. Hsieh, L.-Y. Chang, Y.-C. Huang, H.-C. Lin,

Vaccines for the elderly

Clinical infection services—the Leiden experience

An after-hours clinical liaison blood culture service—is it worth it?

Clinical Microbiology and Infection

The influence of protein binding on the antibacterial activity of faropenem against Haemophilus influenzae I. Gustafsson, O. Cars Clinical Microbiology.

K. Kaier, N.T. Mutters, U. Frank Clinical Microbiology and Infection

Abstracts Clinical Microbiology and Infection

Virology: a scientific discipline facing new challenges

Modelling during an emergency: the 2009 H1N1 influenza pandemic

New oral cephalosporins in pediatric community-acquired infections

B.A. Cunha Clinical Microbiology and Infection

Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group† H. Goossens Clinical.

J.L. Balcázar Clinical Microbiology and Infection

Test results: characterising the antimicrobial activity of daptomycin

G.C. Schito Clinical Microbiology and Infection

Impact of antibiotic restrictions: the patient's perspective

B. Martha, D. Croisier, A. Fanton, K. Astruc, L. Piroth, F. Huet, P

CMI readers' survey Clinical Microbiology and Infection

The future of diagnostic bacteriology

Presentation transcript:

Antimicrobial susceptibility testing in biofilm-growing bacteria M.D. Macia, E. Rojo-Molinero, A. Oliver Clinical Microbiology and Infection Volume 20, Issue 10, Pages 981-990 (October 2014) DOI: 10.1111/1469-0691.12651 Copyright © 2014 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 1 Antimicrobial susceptibility testing with the flow cell biofilm model. (1) Medium bottle, where antibiotics are added and circulate through the flow cell for the required time. (2) Peristaltic pump, which provides laminar flow. (3) Bubble traps, which avoid destructive air bubbles forming on the flow cells. (4) Flow cells, where the biofilm develops. (5) Waste bottle. (a) Typical mushroom structure of Pseudomonas aeruginosa biofilm tagged with green fluorescent protein (GFP). (b) Red propidium iodide staining of dead cells/areas to observe and quantify the bactericidal effect during antibiotic treatment of GFP-tagged P. aeruginosa biofilm. (c) Different structural distribution of a mixed biofilm of two P. aeruginosa strains tagged with enhanced yellow fluorescent protein (outer part) and enhanced cyan fluorescent protein (internal part). Clinical Microbiology and Infection 2014 20, 981-990DOI: (10.1111/1469-0691.12651) Copyright © 2014 European Society of Clinical Infectious Diseases Terms and Conditions